Polycythemia Vera · line 1 · Hydroxyurea (PV / ET high-risk 1L cytoreduction) + baseline phlebotomy/ASA

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-HU-PV-ET`

ID	`IND-PV-1L-PHLEBOTOMY-ASA`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-PV`
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025`

Notes

STANDARD track for PV 1L low-risk. STUB — requires clinical co-lead signoff.

Used By

Algorithms

ALGO-PV-1L - ALGO-PV-1L